WO1999065490A3 - Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders - Google Patents
Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders Download PDFInfo
- Publication number
- WO1999065490A3 WO1999065490A3 PCT/US1999/013100 US9913100W WO9965490A3 WO 1999065490 A3 WO1999065490 A3 WO 1999065490A3 US 9913100 W US9913100 W US 9913100W WO 9965490 A3 WO9965490 A3 WO 9965490A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- apnea
- disorders
- norcisapride
- treatment
- bulimia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14011799A IL140117A0 (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders |
AT99930196T ATE291916T1 (en) | 1998-06-15 | 1999-06-10 | USE OF OPTICALLY PURE (-) NORCISAPRIDE IN THE TREATMENT OF IRGITABLE BOWEL SYNDROME |
BR9911302-3A BR9911302A (en) | 1998-06-15 | 1999-06-10 | Methods to treat bulimia, to treat disorders mediated by vagal activity, to treat irritable bowel syndrome, to treat apnea or apnea disorders, to prevent or control bulimia, disorders mediated by vagal activity, irritable bowel syndrome, bradycardia or bradyarrhythmia, asthma , urinary incontinence, and, apnea or apnea disorders in a patient |
DE69924488T DE69924488T2 (en) | 1998-06-15 | 1999-06-10 | USE OF OPTICALLY PURE (-) NORCISAPRIDE IN THE TREATMENT OF REIZDARY SYNDROME |
AU46784/99A AU764474B2 (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
EP99930196A EP1087765B1 (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-) norcisapride in the treatment of irritable bowel syndrome |
KR1020007014025A KR20010052740A (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders |
JP2000554370A JP2003522103A (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-)-norsis apide to treat apnea, bulimia and other disorders |
HU0102026A HUP0102026A3 (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-) norcisapride for producing pharmaceutical compositions suitable for treating apnea, bulimis, and other disorders |
CA002334369A CA2334369A1 (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
SK1906-2000A SK19062000A3 (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
IS5755A IS5755A (en) | 1998-06-15 | 2000-12-08 | Use of pure light (-) narcotic epidermis in the treatment of respiratory arrest, bulimia and other injuries |
NZ508825A NZ508825A (en) | 1998-06-15 | 2000-12-12 | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders |
NO20006358A NO20006358L (en) | 1998-06-15 | 2000-12-13 | Use of optically pure (-) - norcisapride in the treatment of apnea, bulimia and other diseases |
BG105097A BG105097A (en) | 1998-06-15 | 2000-12-27 | Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders |
HK02101726.7A HK1040059A1 (en) | 1998-06-15 | 2002-03-06 | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8922598P | 1998-06-15 | 1998-06-15 | |
US60/089,225 | 1998-06-15 | ||
US12223699P | 1999-03-01 | 1999-03-01 | |
US60/122,236 | 1999-03-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999065490A2 WO1999065490A2 (en) | 1999-12-23 |
WO1999065490A3 true WO1999065490A3 (en) | 2000-04-13 |
Family
ID=26780367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/013100 WO1999065490A2 (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
Country Status (24)
Country | Link |
---|---|
US (2) | US6559165B1 (en) |
EP (1) | EP1087765B1 (en) |
JP (1) | JP2003522103A (en) |
KR (3) | KR20060020739A (en) |
CN (1) | CN1312716A (en) |
AR (1) | AR020327A1 (en) |
AT (1) | ATE291916T1 (en) |
AU (1) | AU764474B2 (en) |
BG (1) | BG105097A (en) |
BR (1) | BR9911302A (en) |
CA (1) | CA2334369A1 (en) |
CZ (1) | CZ20004736A3 (en) |
DE (1) | DE69924488T2 (en) |
ES (1) | ES2237117T3 (en) |
HK (1) | HK1040059A1 (en) |
HU (1) | HUP0102026A3 (en) |
IL (1) | IL140117A0 (en) |
IS (1) | IS5755A (en) |
NO (1) | NO20006358L (en) |
NZ (3) | NZ526108A (en) |
PL (1) | PL345325A1 (en) |
SK (1) | SK19062000A3 (en) |
TR (6) | TR200103762T2 (en) |
WO (1) | WO1999065490A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7160898B2 (en) | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US6835200B2 (en) | 1999-06-22 | 2004-12-28 | Ndo Surgical. Inc. | Method and devices for tissue reconfiguration |
US6821285B2 (en) | 1999-06-22 | 2004-11-23 | Ndo Surgical, Inc. | Tissue reconfiguration |
US7846180B2 (en) | 1999-06-22 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Tissue fixation devices and methods of fixing tissue |
US6663639B1 (en) | 1999-06-22 | 2003-12-16 | Ndo Surgical, Inc. | Methods and devices for tissue reconfiguration |
US8287554B2 (en) | 1999-06-22 | 2012-10-16 | Ethicon Endo-Surgery, Inc. | Method and devices for tissue reconfiguration |
EP1833467B1 (en) | 2004-12-20 | 2016-08-03 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
GB0524668D0 (en) * | 2005-12-02 | 2006-01-11 | Novartis Ag | Organic compounds |
US8852216B2 (en) | 2007-03-23 | 2014-10-07 | Ethicon Endo-Surgery, Inc. | Tissue approximation methods |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0364274A1 (en) * | 1988-10-13 | 1990-04-18 | Glaxo Group Limited | Imidazole derivatives |
WO1993012785A1 (en) * | 1991-12-21 | 1993-07-08 | Smithkline Beecham Plc | Use of 5-ht4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
WO1994027599A1 (en) * | 1993-05-25 | 1994-12-08 | Laboratoires Glaxo Wellcome S.A. | Rectal compositions |
EP0748807A1 (en) * | 1995-06-13 | 1996-12-18 | Synthelabo | Derivatives of N-(1,4-diazabicyclo(2.2.2)-oct-2-yl)methyl benzamide, their preparation and their therapeutical use |
WO1996040133A1 (en) * | 1995-06-07 | 1996-12-19 | Sepracor Inc. | Optically pure (-) norcisapride for treating digestive tract disorders |
WO1998003173A1 (en) * | 1996-07-19 | 1998-01-29 | Sepracor Inc. | Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
WO1999002496A1 (en) * | 1997-07-11 | 1999-01-21 | Janssen Pharmaceutica N.V. | (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR748807A (en) | 1932-03-10 | 1933-07-10 | Gulf Refining Co | Improvements in the manufacture of hydrocarbons |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4962115A (en) | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
US5137896A (en) | 1981-10-01 | 1992-08-11 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
CA1183847A (en) | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
US5057525A (en) | 1981-10-01 | 1991-10-15 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives |
US4598123A (en) | 1983-07-14 | 1986-07-01 | Unites States Steel Corporation | Impact modified methyl methacrylate polymer |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4800162A (en) | 1987-04-01 | 1989-01-24 | Sepracor, Inc. | Method for resolution of steroisomers in multiphase and extractive membrane reactors |
US5057427A (en) | 1988-04-07 | 1991-10-15 | Sepracor, Inc. | Method for resolution of stereoisomers |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5116407A (en) | 1988-10-13 | 1992-05-26 | Courtaulds Coatings Limited | Antifouling coatings |
JPH02188523A (en) | 1989-01-13 | 1990-07-24 | M S C:Kk | Remedy for apnea in sleeping |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5075290A (en) | 1989-06-28 | 1991-12-24 | University Of Virginia Alumni Patents Foundation | Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5356934A (en) | 1990-03-29 | 1994-10-18 | Eli Lilly And Company | Selected serotonin subtype receptor agonist to treat sleep apnea |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
AU4666393A (en) | 1992-07-07 | 1994-01-31 | Sepracor, Inc. | Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
EP1170010A3 (en) | 1992-07-07 | 2004-05-19 | Sepracor Inc. | Method of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
WO1995001803A1 (en) | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-gastrointestinal motility agent combinations |
US5407953A (en) | 1994-02-04 | 1995-04-18 | Morgan; Julia A. | Treating apnea/hypopnea/snoring in humans |
US5502067A (en) | 1994-02-04 | 1996-03-26 | Morgan; Julia A. | Treating apneahypopnea/snoring in humans |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
SI1089733T1 (en) | 1998-06-15 | 2005-06-30 | Sepracor Inc. | Use of optically pure (+)-norcisapride for treating irritable bowel syndrome |
-
1999
- 1999-06-10 HU HU0102026A patent/HUP0102026A3/en unknown
- 1999-06-10 CA CA002334369A patent/CA2334369A1/en not_active Abandoned
- 1999-06-10 DE DE69924488T patent/DE69924488T2/en not_active Expired - Fee Related
- 1999-06-10 BR BR9911302-3A patent/BR9911302A/en not_active Application Discontinuation
- 1999-06-10 ES ES99930196T patent/ES2237117T3/en not_active Expired - Lifetime
- 1999-06-10 NZ NZ526108A patent/NZ526108A/en unknown
- 1999-06-10 TR TR2001/03762T patent/TR200103762T2/en unknown
- 1999-06-10 KR KR1020067003048A patent/KR20060020739A/en not_active Application Discontinuation
- 1999-06-10 IL IL14011799A patent/IL140117A0/en unknown
- 1999-06-10 KR KR1020007014025A patent/KR20010052740A/en not_active Application Discontinuation
- 1999-06-10 EP EP99930196A patent/EP1087765B1/en not_active Expired - Lifetime
- 1999-06-10 CN CN99809564A patent/CN1312716A/en active Pending
- 1999-06-10 TR TR2001/03758T patent/TR200103758T2/en unknown
- 1999-06-10 KR KR1020067010978A patent/KR20060067985A/en not_active Application Discontinuation
- 1999-06-10 PL PL99345325A patent/PL345325A1/en not_active Application Discontinuation
- 1999-06-10 CZ CZ20004736A patent/CZ20004736A3/en unknown
- 1999-06-10 TR TR2001/03757T patent/TR200103757T2/en unknown
- 1999-06-10 AU AU46784/99A patent/AU764474B2/en not_active Ceased
- 1999-06-10 WO PCT/US1999/013100 patent/WO1999065490A2/en not_active Application Discontinuation
- 1999-06-10 NZ NZ535055A patent/NZ535055A/en unknown
- 1999-06-10 TR TR2001/03760T patent/TR200103760T2/en unknown
- 1999-06-10 TR TR2001/03759T patent/TR200103759T2/en unknown
- 1999-06-10 AT AT99930196T patent/ATE291916T1/en not_active IP Right Cessation
- 1999-06-10 TR TR2000/03707T patent/TR200003707T2/en unknown
- 1999-06-10 SK SK1906-2000A patent/SK19062000A3/en unknown
- 1999-06-10 JP JP2000554370A patent/JP2003522103A/en active Pending
- 1999-06-15 AR ARP990102864A patent/AR020327A1/en unknown
-
2000
- 2000-11-28 US US09/722,391 patent/US6559165B1/en not_active Expired - Fee Related
- 2000-12-08 IS IS5755A patent/IS5755A/en unknown
- 2000-12-12 NZ NZ508825A patent/NZ508825A/en unknown
- 2000-12-13 NO NO20006358A patent/NO20006358L/en unknown
- 2000-12-27 BG BG105097A patent/BG105097A/en unknown
-
2002
- 2002-03-06 HK HK02101726.7A patent/HK1040059A1/en unknown
-
2003
- 2003-02-26 US US10/372,875 patent/US7064138B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0364274A1 (en) * | 1988-10-13 | 1990-04-18 | Glaxo Group Limited | Imidazole derivatives |
WO1993012785A1 (en) * | 1991-12-21 | 1993-07-08 | Smithkline Beecham Plc | Use of 5-ht4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
WO1994027599A1 (en) * | 1993-05-25 | 1994-12-08 | Laboratoires Glaxo Wellcome S.A. | Rectal compositions |
WO1996040133A1 (en) * | 1995-06-07 | 1996-12-19 | Sepracor Inc. | Optically pure (-) norcisapride for treating digestive tract disorders |
EP0748807A1 (en) * | 1995-06-13 | 1996-12-18 | Synthelabo | Derivatives of N-(1,4-diazabicyclo(2.2.2)-oct-2-yl)methyl benzamide, their preparation and their therapeutical use |
WO1998003173A1 (en) * | 1996-07-19 | 1998-01-29 | Sepracor Inc. | Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
WO1999002496A1 (en) * | 1997-07-11 | 1999-01-21 | Janssen Pharmaceutica N.V. | (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders |
Non-Patent Citations (6)
Title |
---|
BLECKER U. ET AL: "The role of ' occult ' gastroesophageal reflux in chronic pulmonary disease in children.", ACTA GASTRO-ENTEROLOGICA BELGICA, (1995) 58/5-6 (348-352)., XP002128488 * |
NOOR N ET AL: "Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, (1998 JUN) 33 (6) 605-11., XP002128489 * |
SHAH M.: "Gastroesophageal reflux - How to mend it?.", INDIAN JOURNAL OF PEDIATRICS, (1996) 63/4 (441-445)., XP002128487 * |
SKINNER S ET AL: "Gastric ulcer presenting as gastroesophageal reflux and apnea in a term neonate.", TEXAS MEDICINE, (1998 SEP) 94 (9) 57-8., XP002128490 * |
VANDENPLAS Y: "Clinical use of cisapride and its risk-benefit in paediatric patients.", EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, (1998 OCT) 10 (10) 871-81. REF: 106, XP002128486 * |
WARD R M ET AL: "Cisapride: a survey of the frequency of use and adverse events in premature newborns.", PEDIATRICS, (1999 FEB) 103 (2) 469-72., XP002128485 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999065571A3 (en) | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders | |
EP1695983A3 (en) | Glucagon-like peptide-1 analogs | |
WO2003018516A3 (en) | Glucagon-like peptide-1 analogs | |
AU2003201880A1 (en) | Solvent-soluble block copolyimide composition and process for producing the same | |
AU2003219942A1 (en) | Composition and process for well cleaning | |
AU2002216218A1 (en) | Naphthalene derivatives which bind to the ep4 receptor | |
AU5274000A (en) | Prevention of regression in refractive keratoplasty | |
AU2003213787A1 (en) | Compositions and methods for the treatment of anorectal disorders | |
WO1999065490A3 (en) | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders | |
AU2728600A (en) | Integrated pyrolysis gasoline treatment process | |
HUP0200399A2 (en) | Macromolecular photocrosslinkers, their use, process for preparation of crosslinked structure from composition containing the same and ophthalmic composition containing the same | |
AU2001261777A1 (en) | Treatment for irritable bowel syndrome and related conditions | |
WO2000051582A3 (en) | Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron | |
AU2002314624A1 (en) | Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes | |
AU6504600A (en) | Injection quill for water treatment | |
AU7527600A (en) | Coking reduction in cracking reactors | |
WO2000010554A3 (en) | Methods and compositions employing optically pure s(+) vigabatrin | |
EP1464333A3 (en) | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders | |
EP1468685A3 (en) | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders | |
WO2000047284A3 (en) | Novel use of orexin receptor antagonists | |
AU2001253521A1 (en) | Haplotypes of the cxcr4 gene | |
AU1522101A (en) | Heparanase inhibitors for the treatment of heart failure | |
AU3822900A (en) | Process for the treatment of fly ash, using hydrochloric acid | |
AU2003225258A1 (en) | Fiber treatment composition | |
AU4116500A (en) | The use of alpha lipoic acid in the antimetastatic treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99809564.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2334369 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 140117 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/07259 Country of ref document: ZA Ref document number: 200007259 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 46784/99 Country of ref document: AU Ref document number: 1020007014025 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 508825 Country of ref document: NZ Ref document number: 19062000 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/012365 Country of ref document: MX Ref document number: 2000/03707 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2000 554370 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-4736 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999930196 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999930196 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007014025 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-4736 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/03759 Country of ref document: TR Ref document number: 2001/03757 Country of ref document: TR Ref document number: 2001/03762 Country of ref document: TR Ref document number: 2001/03760 Country of ref document: TR Ref document number: 2001/03758 Country of ref document: TR Ref document number: 2001/03761 Country of ref document: TR |
|
WWG | Wipo information: grant in national office |
Ref document number: 46784/99 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-4736 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999930196 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007014025 Country of ref document: KR |